GeoVax competitorsClear all

GeoVax's top competitors include Biogen, Otonomy, MyoKardia and Athersys.
GeoVax
GeoVax
GeoVax is a biotechnology company developing human vaccines against infectious diseases including HIV, Ebola and Zika, and for use in cancer immunotherapy.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Founding Date
Founding Date
2001
Founding Date
1978
Founding Date
2008
Founding Date
2012
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Smyrna, US HQ
Locations
Cambridge, US HQ
Vicente López, AR
North Ryde, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Locations
San Diego, US HQ
Locations
South San Francisco, US HQ
Brisbane, US
Locations
Cleveland, US HQ
Canton, US
Employees
Employees
6
Employees
7,4005% decrease
Employees
49
Employees
23542% increase
Employees
8311% increase
Valuation ($)
Valuation ($)
5.1 m
Valuation ($)
43.2 b
Valuation ($)
176.5 m
Valuation ($)
7 b
Valuation ($)
408.6 m
Twitter followers
Twitter followers
1.3 k
Twitter followers
33.9 k
Twitter followers
226
Twitter followers
1 k
Twitter followers
2 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
51
Number of tweets (last 30 days)
57
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
7
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
2.7
Average likes per tweet (last 30 days)
35.8
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
20.7
Average likes per tweet (last 30 days)
30.7
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
92.16%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
338883
Alexa Website Rank
254464
Alexa Website Rank
339305
Alexa Website Rank
239431
Alexa Website Rank
322595
Employee Rating
Employee Rating
5
Employee Rating
3.8
Employee Rating
4.3
Employee Rating
4.2
Employee Rating
5

Financial

Revenue (est.)
Revenue (est.)
$1.2m (FY, 2019)
Revenue (est.)
$14.4b (FY, 2019)
Revenue (est.)
$600k (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
$5.6m (FY, 2019)
Cost of goods
Cost of goods
N/A
Cost of goods
$2b (FY, 2019)
Cost of goods
$912k (FY, 2019)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$12.4b (FY, 2019)
Gross profit
($312k) (FY, 2019)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($2.4m) (FY, 2019)
Net income
$5.9b (FY, 2019)
Net income
($44.7m) (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
($44.6m) (FY, 2019)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
21 (FY, 2019)
Patents (US)
N/A
Patents (US)
2 (FY, 2018)
Patents (US)
21 (FY, 2016)
Patents Issued
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
11 (Q2, 2020)
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
10 (Q2, 2020)
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q2, 2020)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
N/A
Pre-Clinical Phase Products
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
3 (FY, 2018)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
$ 5.8m
Total funding raised
N/A
Total funding raised
$ 153.4m
Total funding raised
$ 98m
Total funding raised
$ 9m
For sources of this data, please see the company profile

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
83↑ 11% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company